It announced on May 9, 2013, that Xtandi had generated sales of $75.4 million. This was substantial revenue, as this was an increase of $18 million over the previous quarter. Going forward, operating expenses are estimated to be around $300 million. The company is looking at expanding Xtandi to earlier prostate cancer treatments and other indications like breast cancer.
I have to say that at least patients with prostate cancer have a wide variety of treatments. The more treatments there are, the better, and this sector is set to grow even more in the future to about $5 billion as mentioned above. Each company has its own methods in terms of what treatment can be provided and the efficacy of the drug.
Despite this, I think that these biotechs can continue to develop more treatments for prostate cancer patients, and investors can definitely invest in these biotechs for long-term gains.
Terry Chrisomalis has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson.
The article Biotechs With Prostate Cancer Treatments originally appeared on Fool.com.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.